130 related articles for article (PubMed ID: 8690513)
1. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Toffoli G; Corona G; Simone F; Gigante M; De Angeli S; Boiocchi M
Int J Cancer; 1996 Jul; 67(1):129-37. PubMed ID: 8690513
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
5. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Kuffel MJ; Ames MM
Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of chronic oral daily administration of idarubicin.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Rimondi G; Bearz A; Stocco F; Robieux I; Boiocchi M
Haematologica; 1997; 82(5 Suppl):1-3. PubMed ID: 9402745
[TBL] [Abstract][Full Text] [Related]
9. Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Weiss M; Giessler C; Kang W
Anticancer Drugs; 2006 Jan; 17(1):69-74. PubMed ID: 16317292
[TBL] [Abstract][Full Text] [Related]
10. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
11. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
13. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Toffoli G; Sorio R; Basso B; Aita P; Corona G; Rupolo M; Boiocchi M
J Chemother; 2004 Apr; 16(2):193-200. PubMed ID: 15216956
[TBL] [Abstract][Full Text] [Related]
15. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
Kang W; Weiss M
Drug Metab Dispos; 2003 Apr; 31(4):462-8. PubMed ID: 12642473
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
18. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
[TBL] [Abstract][Full Text] [Related]
19. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
20. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wu M; Wang B; Perchellet EM; Sperfslage BJ; Stephany HA; Hua DH; Perchellet JP
Anticancer Drugs; 2001 Nov; 12(10):807-19. PubMed ID: 11707648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]